Neoadjuvant chemotherapy for Ewing's tumour of bone: Recent experience at the Rizzoli Orthopaedic Institute

European Journal of Cancer

Volumn 38, Issue 17, 2002, Pages 2243-2251

  Bacci, G ^a   Mercuri, M ^a   Longhi, A ^a   Bertoni, F ^a   Barbieri, E ^b   Donati, D ^a   Giacomini, S ^a   Bacchini, P ^a   Pignotti, E ^a   Forni, C ^a   Ferrari, S ^a  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Ewing's sarcoma; Neoadjuvant chemotherapy; Radiotherapy; Surgery

Indexed keywords

CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; VINCRISTINE;

ADJUVANT CHEMOTHERAPY; ADOLESCENT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; EWING SARCOMA; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; STATISTICAL SIGNIFICANCE; TOXICITY; TREATMENT OUTCOME;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; PATIENT COMPLIANCE; SARCOMA, EWING'S;

EID: 0036848070     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00148-X     Document Type: Article

References (27)

1. Boyer C.W., Brickner T.J., Perry R.H. Ewing's sarcoma. case against surgery Cancer. 20:1967;1602-1606.
2. Falk S., Alpert M. Five-year survival of patients with Ewing's sarcoma. Surg Gynecol Obstet. 124:1967;319-324.
3. Bacci G., Toni A., Avella M.et al. Long-term results in patients treated with combined therapy. Cancer. 63:1989;1477-1486.
4. Bacci G., Picci P., Ferrari S.et al. Neoadjuvant chemotherapy for Ewing's sarcoma of bone. no benefit observed after adding ifosfamide and etoposide to vincristine, actinomycin, cyclophosphamide, and doxorubicin in the maintenance phase Results of two sequential studies. Cancer. 82:1998;1174-1183.
5. Burgert E.O., Nesbit M.E., Garnsey L.A.et al. Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone. intergroup study IESS-II J Clin Oncol. 8:1990;1514-1524.
6. Craft A.W., Cotterill S., Imeson J. Improvement in survival for Ewing's sarcoma by substitution of ifosfamide for cyclophosphamide. Am J Pediat Hematol Oncol. 15:1993;31-35.
7. Craft A.W., Cotterill S., Bullimore J.A.et al. Long-term results from the first UKCCSG Ewing's tumour study (ET-1). Eur J Cancer. 33:1997;1061-1069.
8. Elomaa I., Blomqvist C.P. saeter, G, et al. Five-year results in Ewing's sarcoma. The Scandinavian Sarcoma Group Experience with the SSG-IX protocol. Eur J Cancer. 36:2000;875-880.
9. Jurgens H., Exner U., Gadner H.et al. Multidisciplinary treatment of primary Ewing's sarcoma of bone. Cancer. 61:1988;23-32.
10. Nesbit M.E., Gehan E.A., Burgert E.O.et al. Multimodal therapy for the management of primary nonmetastatic Ewing's sarcoma of bone. a long-term follow-up of the first intergroup study J Clin Oncol. 8:1990;1664-1674.
11. Oberlin O., Habrand J.L., Zucker J.M.et al. No benefit of ifofasfamide in Ewing's sarcoma. a nonrandomized study of the French Society of Pediatric Oncology J Clin Oncol. 10:1992;1407-1412.
12. Rosen G., Caparros B., Mosende C.et al. Curability of Ewing's sarcoma and considerations for future therapeutic trials. Cancer. 41:1978;888-899.
13. Picci P., Bohling T. Bacci, G, et al. Chemotherapy-induced tumour necrosis as a prognostic factor in localized Ewing's sarcoma of the extremities. J Clin Oncol. 15:1997;1553-1559.
14. Picci P., Rougraff B.T., Bacci G.et al. Prognostic significance of histopathologic response to chemotherapy in nonmetastatic Ewing's sarcoma of the extremities J Clin Oncol. 11:1993;1763-1769.
15. Rosito P., Mancini A.F., Rondelli R.et al. Italian Cooperative Study for the treatment of children and young adults with localized Ewing's sarcoma of bone. a preliminary report of 6 years of experience Cancer. 86:1999;421-428.
16. Gobel V., Jurgens H., Etspuler G.et al. Prognostic significance of tumour volume in localized Ewing's sarcoma of bone in children and adolescents. J Cancer Res Clin Oncol. 113:1987;187-191.
17. Barbieri E., Frezza G., Martelli O.et al. Non conventional fractionated radiotherapy of the musculo-skeletal sarcomas. Tumori. 84:1998;167-170.
18. Enneking W., Dunham W., Gebhardt M.et al. A system for the classification of skeletal resections. Chir Organi Mov. 75:1990;217-240.
19. Dunst J., Hoffmann C., Ahrens S., Jurgens H. Surgery versus radiotherapy in Ewing's sarcoma with good prognosis. Analysis of the CESS 86 data. Strahlenther Onkol. 172:1996;244-248.
20. Oberlin O., Habrand J.L., Zucker J.M.et al. No benefit of ifofasfamide in Ewing's sarcoma. a nonrandomized study of the French Society of Pediatric Oncology J Clin Oncol. 10:1992;1407-1412.
21. Paulussen M., Ahrens S., Dunst J.et al. Localized Ewing tumour of bone. final results of the cooperative Ewing's sarcoma study CESS 86 J Clin Oncol. 19:2001;1818-1829.
22. Ozaki T., Hillmann A., Hoffmann C.et al. Ewing's sarcoma of the femur. Acta Orthop Scand. 68:1997;20-24.
23. Terek R.M., Brien E.W., Marcove R.C.et al. Treatment of femoral Ewing's sarcoma. Cancer. 78:1996;70-78.
24. Wilkins R.M., Pritchard D.J., Burgert E.O.et al. Ewing's sarcoma of bone. Experience with 140 patients Cancer. 58:1986;2551-2555.
25. Bacci G., Ferrari S., Bertoni F.et al. Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy. analysis of 359 patients at the Istituto Ortopedico Rizzoli J Clin Oncol. 18:2000;4-11.
26. Cotterill S.J., Ahrens S., Paulussen M.et al. Prognostic factors in Ewing's tumour of bone. analysis of 975 patients from the European Intergroup Cooperative Ewing's sarcoma Study Group J Clin Oncol. 18:2000;3108-3114.
27. Grier H., Krailo M., Link M.et al. Improved outcome in non-metastatic Ewing's sarcoma (EWS) and PNET of bone with the addition of ifosfamide (I) and etoposide (E) to vincristine (V), adriamycin (Ad), cyclophosphamide (C), and actinomycin (A): a Childrens Cancer Group (CCG) and Pediatric Oncology Group (POG) report. Proccedings of ASCO. 13:1994;421. (abstr 1443).